Association of bronchial steroid inducible methylation quantitative trait loci with asthma and chronic obstructive pulmonary disease treatment response

Elise M.A. Slob*, Alen Faiz, Jos van Nijnatten, Susanne J.H. Vijverberg, Cristina Longo, Merve Kutlu, Fook Tim Chew, Yang Yie Sio, Esther Herrera-Luis, Antonio Espuela-Ortiz, Javier Perez-Garcia, Maria Pino-Yanes, Esteban G. Burchard, Uroš Potočnik, Mario Gorenjak, Colin Palmer, Cyrielle Maroteau, Steve Turner, Katia Verhamme, Leila KarimiSomnath Mukhopadhyay, Wim Timens, Pieter S. Hiemstra, Mariëlle W. Pijnenburg, Margaret Neighbors, Michele A. Grimbaldeston, Gaik W. Tew, Corry A. Brandsma, Vojko Berce, Hananeh Aliee, Fabian Theis, Don D. Sin, Xuan Li, Maarten van den Berge, Anke H. Maitland-van der Zee, Gerard H. Koppelman

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

1 Downloads (Pure)
Original languageEnglish
Article numbere12173
JournalClinical and Translational Allergy
Volume12
Issue number8
DOIs
Publication statusPublished - Aug 2022

Bibliographical note

Funding Information:
The Netherlands Organisation for Scientific Research; the Dutch Asthma Foundation; GlaxoSmithKline, the University Medical Center Groningen; Leiden University Medical Center. Genentech Inc.; Lung Foundation Netherlands, Grant/Award Number: number 5.1.16.094; GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences; Slovenian Research Agency, Grant/Award Number: P3‐0067; SysPharmPedia grant; the Ministry of Education, Science and Sport Slovenia (MIZS), Grant/Award Number: C3330‐16‐500106; Sandler Family Foundation; The American Asthma Foundation, the RWJF Amos Medical Faculty Development Program; The National Heart, Lung, and Blood Institute of the National Institutes of Health, Grant/Award Number: R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, R01HL141845; National Institute of Health and Environmental Health Sciences, Grant/Award Number: R01ES015794, R21ES24844; The National Institute on Minority Health and Health Disparities, Grant/Award Number: P60MD006902, RL5GM118984, R01MD010443, and R56MD013312; the Tobacco‐Related Disease Research Program, Grant/Award Number: 24RT‐0025, 27IR‐0030; National Human Genome Research Institute, Grant/Award Number: U01HG009080; ISCIII and ERDF; Ramón y Cajal Program by the Spanish Ministry of Science, Innovation, and Universities, Grant/Award Number: RYC‐2015‐17205; MICIU, FPU19/02175; The State Research Agency; The European Union, Grant/Award Number: MICIU/AEI/FEDER, UE, SAF2017‐83417R; MICIU fellowship, Grant/Award Number: PRE2018‐083837; MICIU/ULL (M‐ULL); Slovenian Research Agency, Grant/Award Number: P3‐0067; SysPharmPedia, The Ministry of Education, Science and Sport Slovenia, Award Number: C3330‐16‐500106; Roche Diagnostics GmbH and Cellarity Inc.

Funding Information:
E.M.A. Slob, A. Faiz, S.J.H. Vijverberg, H. Aliee, J. van Nijnatten, P. Hiemstra, C. Maroteau, C. Palmer, M. Kutlu, S. Turner, S. Mukhopadhyay, M. Gorenjak, C.A. Brandsma, L. Karimi, Y.Y. Sio, C. Longo and M.W. Pijnenburg have nothing to disclose. F.T. Chew reports grants from Singapore Ministry of Education Academic Research Fund, Singapore Immunology Network, National Medical Research Council (NMRC) (Singapore), Biomedical Research Council (BMRC) (Singapore), and the Agency for Science Technology and Research (A*STAR) (Singapore), during the conduct of the study; and consulting fees from Sime Darby Technology Centre; First Resources Ltd; Genting Plantation, and Olam International, outside the submitted work. M. Pino‐Yanes reports grants from the Spanish Ministry of Science, Innovation, and Universities, the State Research Agency, and the European Regional Development Fund from the European Union (MICIU/AEI/FEDER, UE). E. Herrera‐Luis and J. Perez‐Garcia report a fellowships from MICIU. A. Espuela‐Ortiz declares a fellowship granted by MICIU/ULL. E.G. Burchard reports grants from the National Institutes of Health, the Tobacco‐Related Disease Research Program, the Sandler Family Foundation, the American Asthma Foundation, the Amos Medical Faculty Development Program from the Robert Wood Johnson Foundation, and from the Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences II. W. Timens reports fees to the UMCG from Roche Diagnostics/Ventana, personal fees from Merck Sharp Dohme, Bristol‐Myers‐Squibb and AbbVie, outside the submitted work. G.H. Koppelman reports grants from Lung Foundation of the Netherlands, UBBO EMMIUS Foundation, TETRI Foundation, TEVA the Netherlands, Vertex, GSK, European Union (H2020 Prominent Grant), outside the submitted work; and he has acted on advisory board meetings of GSK and Pure IMS, outside the submitted work. A.H. Maitland‐van der Zee has received research grants outside the submitted work from GSK, Boehringer Íngelheim and Vertex, she is the PI of a P4O2 (Precision Medicine for more Oxygen) public private partnership sponsored by Health Holland involving many private partners that contribute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib‐U, Smartfish, SODAQ, Thirona, TopMD and Novartis), and she has served in advisory boards for AstraZeneca, GSK and Boehringer Ingelheim with money paid to her institution. Dr. van den Berge reports grants to University from GlaxoSmithKline, Novartis, Genentech, outside the submitted work. Dr. Potočnik reports grants from Slovenian Research Agency, grants from Ministry of Education, Science and Sport Slovenia (MIZS), during the conduct of the study. M. Grimbaldeston, G.W. Tew and M. Neighbors are employees of Genentech Inc., a Member of the Roche Group. K. Verhamme works for a research department which receives/received unconditional research grants from Yamanouchi, Pfizer‐Boehringer Ingelheim, Novartis, GSK, Chieisi, Amgen, UCB, none of which are related to the content of this work. F.J. Theis acknowledges support by the BMBF (grant #L031L0214A, grant# 01IS18036B and grant# 01IS18053A) and by the Helmholtz Association's Initiative and Networking Fund through Helmholtz AI [grant number: ZT‐I‐PF‐5‐01] and sparse2big [grant number ZT‐I‐007]. V. Berce reports grants from Slovenian Research Agency, grants from Ministry of Education, Science and Sport Slovenia (MIZS), during the conduct of the study.

Funding Information:
The GLUCOLD study (for which these are secondary analyses) was supported by the Netherlands Organisation for Scientific Research (NWO), the Dutch Asthma Foundation, GlaxoSmithKline, the University Medical Center Groningen, and Leiden University Medical Center. Genentech Inc. funded the GLUCOLD bronchial biopsy RNA sequencing project. E.M.A. Slob, S.J.H. Vijverberg, A.H. Maitland‐van der Zee, G.H. Koppelman and M.W. Pijnenburg are conducting the PUFFIN trial that is supported by the Lung Foundation Netherlands, grant number 5.1.16.094. The PACMAN cohort study was funded by a strategic alliance between GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences. The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3‐0067) and from the SysPharmPedia grant, co‐financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330‐16‐500106). The Genes‐environments and Admixture in Latino Americans (GALA II) Study and the Study of African Americans, Asthma, Genes and Environments (SAGE) were supported in part by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the National Heart, Lung, and Blood Institute of the National Institutes of Health R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, R01HL141845, National Institute of Health and Environmental Health Sciences R01ES015794, R21ES24844, the National Institute on Minority Health and Health Disparities P60MD006902, RL5GM118984, R01MD010443, and R56MD013312, the Tobacco‐Related Disease Research Program under Award Number 24RT‐0025, 27IR‐0030 and the National Human Genome Research Institute U01HG009080. The genotyping service of PAGES was carried out at CEGEN‐PRB3‐ISCIII, supported by grant PT17/0019 of the PE I+D+i 2013–2016, funded by ISCIII and ERDF. Maria Pino‐Yanes was funded by the Ramón y Cajal Program by the Spanish Ministry of Science, Innovation, and Universities (MICIU) (RYC‐2015‐17205) and by a grant by MICIU, the State Research Agency, and the European Regional Development Fund from the European Union (MICIU/AEI/FEDER, UE, SAF2017‐83417R). Esther Herera‐Luis was supported by a MICIU fellowship (PRE2018‐083837). Javier Perez‐Garcia was also supported by a Ph.D. fellowship (FPU19/02175) granted by MICIU. Antonio Espuela‐Ortiz was supported by a fellowship granted by MICIU/ULL (M‐ULL). The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3‐0067) and from the SysPharmPedia grant, co‐financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330‐16‐500106). F.J. Theis reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and ownership interest in Cellarity, Inc. and Dermagnostix.

Funding Information:
The GLUCOLD study (for which these are secondary analyses) was supported by the Netherlands Organisation for Scientific Research (NWO), the Dutch Asthma Foundation, GlaxoSmithKline, the University Medical Center Groningen, and Leiden University Medical Center. Genentech Inc. funded the GLUCOLD bronchial biopsy RNA sequencing project. E.M.A. Slob, S.J.H. Vijverberg, A.H. Maitland-van der Zee, G.H. Koppelman and M.W. Pijnenburg are conducting the PUFFIN trial that is supported by the Lung Foundation Netherlands, grant number 5.1.16.094. The PACMAN cohort study was funded by a strategic alliance between GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences. The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3-0067) and from the SysPharmPedia grant, co-financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330-16-500106). The Genes-environments and Admixture in Latino Americans (GALA II) Study and the Study of African Americans, Asthma, Genes and Environments (SAGE) were supported in part by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the National Heart, Lung, and Blood Institute of the National Institutes of Health R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, R01HL141845, National Institute of Health and Environmental Health Sciences R01ES015794, R21ES24844, the National Institute on Minority Health and Health Disparities P60MD006902, RL5GM118984, R01MD010443, and R56MD013312, the Tobacco-Related Disease Research Program under Award Number 24RT-0025, 27IR-0030 and the National Human Genome Research Institute U01HG009080. The genotyping service of PAGES was carried out at CEGEN-PRB3-ISCIII, supported by grant PT17/0019 of the PE I+D+i 2013–2016, funded by ISCIII and ERDF. Maria Pino-Yanes was funded by the Ramón y Cajal Program by the Spanish Ministry of Science, Innovation, and Universities (MICIU) (RYC-2015-17205) and by a grant by MICIU, the State Research Agency, and the European Regional Development Fund from the European Union (MICIU/AEI/FEDER, UE, SAF2017-83417R). Esther Herera-Luis was supported by a MICIU fellowship (PRE2018-083837). Javier Perez-Garcia was also supported by a Ph.D. fellowship (FPU19/02175) granted by MICIU. Antonio Espuela-Ortiz was supported by a fellowship granted by MICIU/ULL (M-ULL). The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3-0067) and from the SysPharmPedia grant, co-financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330-16-500106). F.J. Theis reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and ownership interest in Cellarity, Inc. and Dermagnostix.

Cite this